PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
10.35%
Revenue growth above 1.5x 6247.T's 4.12%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
-3.36%
Negative gross profit growth while 6247.T is at 7.48%. Joel Greenblatt would examine cost competitiveness or demand decline.
-38.35%
Negative EBIT growth while 6247.T is at 20.57%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-18.20%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-55.37%
Negative net income growth while 6247.T stands at 18.42%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-55.32%
Negative EPS growth while 6247.T is at 18.42%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-55.32%
Negative diluted EPS growth while 6247.T is at 18.42%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-93.11%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-26.07%
Negative 5Y CAGR while 6247.T stands at 26.61%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-7.29%
Negative 3Y CAGR while 6247.T stands at 21.82%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
92.77%
Below 50% of 6247.T's 591.30%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-2690.48%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-152.21%
Negative 3Y CAGR while 6247.T is 145.95%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
52.20%
5Y equity/share CAGR above 1.5x 6247.T's 18.99%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
35.88%
3Y equity/share CAGR above 1.5x 6247.T's 8.32%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.62%
Firm’s AR is declining while 6247.T shows 8.95%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
12.04%
Inventory growth well above 6247.T's 2.66%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.21%
Asset growth well under 50% of 6247.T's 2.95%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
-3.64%
We have a declining book value while 6247.T shows 1.69%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
9.70%
Debt growth of 9.70% while 6247.T is zero. Bruce Berkowitz sees additional leverage that must yield profitable expansions to be worthwhile.
-100.00%
Our R&D shrinks while 6247.T invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
2.92%
SG&A declining or stable vs. 6247.T's 11.17%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.